Akero Therapeutics Management
Management criteria checks 2/4
Akero Therapeutics' CEO is Andrew Cheng, appointed in Sep 2018, has a tenure of 6.67 years. total yearly compensation is $10.47M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth €14.57M. The average tenure of the management team and the board of directors is 6.1 years and 6.1 years respectively.
Key information
Andrew Cheng
Chief executive officer
US$10.5m
Total compensation
| CEO salary percentage | 6.55% |
| CEO tenure | 6.7yrs |
| CEO ownership | 0.5% |
| Management average tenure | 6.1yrs |
| Board average tenure | 6.1yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$269m |
| Dec 31 2024 | US$10m | US$686k | -US$252m |
| Sep 30 2024 | n/a | n/a | -US$237m |
| Jun 30 2024 | n/a | n/a | -US$204m |
| Mar 31 2024 | n/a | n/a | -US$179m |
| Dec 31 2023 | US$9m | US$660k | -US$152m |
| Sep 30 2023 | n/a | n/a | -US$120m |
| Jun 30 2023 | n/a | n/a | -US$116m |
| Mar 31 2023 | n/a | n/a | -US$112m |
| Dec 31 2022 | US$10m | US$624k | -US$112m |
| Sep 30 2022 | n/a | n/a | -US$121m |
| Jun 30 2022 | n/a | n/a | -US$110m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | US$4m | US$570k | -US$101m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$95m |
| Mar 31 2021 | n/a | n/a | -US$82m |
| Dec 31 2020 | US$5m | US$523k | -US$79m |
| Sep 30 2020 | n/a | n/a | -US$65m |
| Jun 30 2020 | n/a | n/a | -US$59m |
| Mar 31 2020 | n/a | n/a | -US$50m |
| Dec 31 2019 | US$5m | US$450k | -US$44m |
| Sep 30 2019 | n/a | n/a | -US$90m |
| Jun 30 2019 | n/a | n/a | -US$86m |
| Mar 31 2019 | n/a | n/a | -US$87m |
| Dec 31 2018 | US$1m | US$133k | -US$82m |
Compensation vs Market: Andrew's total compensation ($USD10.47M) is above average for companies of similar size in the Italian market ($USD3.30M).
Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.
CEO
Andrew Cheng (57 yo)
6.7yrs
Tenure
US$10,465,855
Compensation
Dr. Andrew Cheng, MD, PhD, serves as Director of Vera Therapeutics, Inc. since May 2017. He served as Director of Arbutus Biopharma Corporation since August 17, 2019 until May 25, 2022. He served as Chief...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.7yrs | US$10.47m | 0.51% € 14.6m | |
| Co-Founder | 6.7yrs | US$3.04m | 0.25% € 7.0m | |
| Executive VP | 6.1yrs | US$3.07m | 0.0014% € 41.4k | |
| Chief Technical Officer | 1.1yrs | US$6.22m | 0% € 0 | |
| Executive VP & Chief Development Officer | 6.6yrs | US$3.04m | 0.048% € 1.4m | |
| Co-Founder & Chief Scientific Officer | 8.1yrs | US$3.49m | 0.15% € 4.2m | |
| Senior VP & Head of Legal | less than a year | no data | no data | |
| Senior VP & Head of Finance | 1.3yrs | no data | no data | |
| Senior Vice President of Commercial Strategy | 2.3yrs | no data | 0.0027% € 77.4k |
6.1yrs
Average Tenure
53yo
Average Age
Experienced Management: 1AKRO's management team is seasoned and experienced (6.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.3yrs | US$10.47m | 0.51% € 14.6m | |
| Independent Director | 6.1yrs | US$478.38k | 0.36% € 10.2m | |
| Independent Director | 6.1yrs | US$499.63k | 0% € 0 | |
| Independent Chairman of the Board | 6.5yrs | US$519.63k | 0% € 0 | |
| Independent Director | 4.9yrs | US$494.63k | 0% € 0 | |
| Independent Director | 6.9yrs | US$492.13k | 0.0027% € 77.7k | |
| Independent Director | 4.1yrs | US$487.13k | 0% € 0 | |
| Independent Director | 3.8yrs | US$484.63k | 0% € 0 |
6.1yrs
Average Tenure
58yo
Average Age
Experienced Board: 1AKRO's board of directors are considered experienced (6.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 14:43 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akero Therapeutics, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Alexandria Hammond | BofA Global Research |
| Edward Nash | Canaccord Genuity |